Suchergebnisse - "Ofran, Yishai"

PubPharm (141)

11

Decreased melanoma CSF-1 secretion by Cannabigerol treatment reprograms regulatory myeloid cells and reduces tumor progression

enthalten in: Oncoimmunology | 2023

von Wyrobnik, I. | Steinberg, M. | Gelfand, A. | +7

12

The increasingly blurred line between induction, consolidation and maintenance in acute myeloid leukaemia

enthalten in: British Journal of Haematology | 2023

von Frisch, A. | Rowe, J. | Ofran, Y.

13

Venetoclax‐based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia

enthalten in: European Journal of Haematology | 2023

von Canaani, J. | Frisch, A. | Pollyea, D. | +11

14

Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study

enthalten in: American journal of hematology | 2022

von Jonas, B. | DiNardo, C. | Fracchiolla, N. | +13

15

CELLS AND METHODS FOR IMPROVED IMMUNOTHERAPY

enthalten in: Europäisches Patentamt | 2022

von LOURIA-HAYON IGAL | OFRAN YISHAI | HAYUN MICHAL

16

Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia : a real-world, multi-center, matched analysis

enthalten in: Annals of hematology | 2022

von Shimony, S. | Canaani, J. | Kugler, E. | +12

ErratumIn: Ann Hematol. 2022 Jul 23;:. - PMID 35869985

17

Correction to : Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real‑world, multi‑center, matched analysis

enthalten in: Annals of hematology | 2022

von Shimony, S. | Canaani, J. | Kugler, E. | +12

ErratumFor: Ann Hematol. 2022 Sep;101(9):2001-2010. - PMID 35739428

18

Compromised activity of natural killer cells in diffuse large b-cell lymphoma is related to lymphoma-induced modification of their surface receptor expression

enthalten in: Cancer immunology immunotherapy | 2022

von Azoulay, T. | Slouzky, I. | Karmona, M. | +5

19

Compromised activity of natural killer cells in diffuse large b-cell lymphoma is related to lymphoma-induced modification of their surface receptor expression

enthalten in: Cancer immunology immunotherapy | 2022

von Azoulay, T. | Slouzky, I. | Karmona, M. | +5

20

Compromised activity of natural killer cells in diffuse large b-cell lymphoma is related to lymphoma-induced modification of their surface receptor expression

enthalten in: Cancer immunology immunotherapy | 2022

von Azoulay, T. | Slouzky, I. | Karmona, M. | +5